<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2778,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344, 104 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/7c87ed6b284de02381b4d0c95e838674'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/7c87ed6b284de02381b4d0c95e838674'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1I6FGG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I6FGG003">Previous Result: <span>United States v. Smith, Criminal Case No...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1I6FGI003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I6FGI003">Next Result: <span>Cumulus Broadcasting v. Okesson, CIV. NO...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344, 104 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion'>
Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344, 104 U.S.P.Q.2d 1641 (Fed. Cir....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344, 104 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I6ENS003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Santarus, Inc. v. Par Pharmaceutical, Inc.</div>
<div class='displayCitation'>104 U.S.P.Q.2d 1641</div>
<div class='displayCitation'>2012 BL 224969</div>
<div class='displayCitation'>694 F.3d 1344</div>
<div class='displayCitation'>bna a0d4k3t1u4</div>
<div class='displayCitation'>bna a0d5f8c5r0</div>
<div class='displayCitation'>wkffecase:26320254</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I6ENS003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344, 104 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Santarus, Inc. v. Par Pharmaceutical, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1I6ENS003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I6ENS003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I6ENS003" /><input id="title" name="title" type="hidden" value="Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344, 104 U.S.P.Q.2d 1641 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="7c87ed6b284de02381b4d0c95e838674" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I6ENS003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%37c%38%37ed%36b%32%38%34de%30%32%33%38%31b%34d%30c%39%35e%38%33%38%36%37%34%2Fdocument%2FX%31I%36ENS%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/bcite/X1I6ENS003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/bcite/X1I6ENS003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/bcite/X1I6ENS003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/related_content/X1I6ENS003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1724924166147";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">694 F.3d 1344</div>
<div class="cite" data-cite-type="ReporterOfDecisions">104 U.S.P.Q.2d 1641</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2010-1360, 2010-1380.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 224969</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
SANTARUS, INC., Plaintiff-Appellant, and The Curators of the University of
Missouri, Plaintiff-Appellant, v. PAR PHARMACEUTICAL, INC., Defendant-Cross
Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2010-1360, 2010-1380.
</center></p>
<p><center>
September 4, 2012.
<span CLASS="page_no" data-cite="104 uspq 2d 1643" data-cite-type="ReporterOfDecisions" data-cite-pageno="1643" data-primary-citation="104 U.S.P.Q.2d 1641">[**1643]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929782" href="#headnote_ref_pq2-dec_929782">[1]</a> <span>Practice and procedure in Patent and Trademark Office &mdash;
Prosecution &mdash; Duty of candor &mdash; Citation of references </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=110.0903.08" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="110.0903.08">&#9658;110.0903.08</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Infringement &mdash; Defenses &mdash; Fraud or unclean hands </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.1111" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.1111">&#9658;120.1111</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Patents directed to formulations of benzimidazole proton pump inhibitors
(PPIs) useful for treating stomach acid-related diseases and disorders, which can be administered as liquid suspension of solid uncoated PPI together with buffering agent, are not unenforceable for inequitable conduct on ground that inventor, assignee university, and counsel were tardy in informing U.S. Patent and Trademark Office that inventor had made uncoated PPI formulation, administered it to hospital patients, and had informed colleagues and recorded medication and test results in hospital records before filing date of first patent application, since inventor testified that he was unaware that experimental development required disclosure, and although federal district court found that such explanation &ldquo;strained credibility,&rdquo; affirmative intent to deceive was not shown by clear and convincing evidence.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929783" href="#headnote_ref_pq2-dec_929783">[2]</a> <span>Practice and procedure in Patent and Trademark Office &mdash;
Prosecution &mdash; Filing date </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=110.0906" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="110.0906">&#9658;110.0906</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Specification &mdash; Written description </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1103" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1103">&#9658;115.1103</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Claims directed to formulations of benzimidazole proton pump inhibitors
(PPIs) useful for treating stomach acid-related diseases and disorders, &ldquo;wherein the composition contains no sucralfate,&rdquo; are not invalid for inadequate written description on ground that specification does not include evidence demonstrating that sucralfate is &ldquo;contraindicated,&rdquo;
since specification states that claimed formulations represent &ldquo;advantageous alternative&rdquo; to use of sucralfate, since claims may state exclusion of alternatives, and limitation specifying that patented formulation is not administered in conjunction with sucralfate permissibly narrowed claims to this preferred use of formulations, and since negative claim limitation is adequately supported if specification describes reason to exclude it, and limitation at issue is adequately supported by specification statements expressly identifying disadvantages of using sucralfate; federal district court's holding that patent cannot claim priority date of parent application is reversed, and patent that issued from parent thus cannot be used as prior art against asserted claims, since holding was based solely on finding of inadequate written description for &ldquo;no sucralfate&rdquo; limitation.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929784" href="#headnote_ref_pq2-dec_929784">[3]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnote_text">
Prior art patent directed to method of treating gastric acid disorders using formulation of omeprazole, both in conventional dosage forms and as aqueous suspension with buffering agent, which teaches that omeprazole need not be enterically coated, renders obvious asserted claims of continuation patent directed to formulations composed of proton pump inhibiting (PPI) agent and buffering agent in pharmaceutically acceptable carrier, since prior patent discloses non-enteric coated PPIs and buffer within ratios required by asserted claims, as well as use of sodium bicarbonate as buffering agent in amount that overlaps with claimed range, and since prior patent would also render obvious limitations reciting specific blood serum concentrations of PPI, in that initial blood serum concentration resulting from PPI dosage is inherent property of formulation, there is no dispute that claimed blood serum concentrations are expected in light of specified dosages, and obvious formulation cannot become nonobvious simply by administering it to patient and claiming resulting serum concentrations. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929785" href="#headnote_ref_pq2-dec_929785">[4]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Reference that teaches that options for formulating omeprazole to treat gastric acid disorders are limited because it is minimally soluble in water but degrades quickly in acidic environment of stomach, and that specifically &ldquo;rules out&rdquo; non-enteric coated conventional oral dosage forms such as tablets, capsules, or granules because they would degrade too quickly in stomach to be effective, would discourage person of ordinary skill in art from pursuing conventional oral dosage forms such as tablets, capsules, or granules with non-enteric coated proton pump inhibitors (PPIs); reference thus &ldquo;teaches away&rdquo;
from such formulations, and federal district court's determination that reference rendered obvious asserted claims directed to conventional dosage forms, such as tablets or capsules, containing non-enteric coated PPIs, is reversed.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929786" href="#headnote_ref_pq2-dec_929786">[5]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnote_text">
Reference that teaches that options for formulating omeprazole to treat gastric acid disorders are limited because it is minimally soluble in water but degrades quickly in acidic environment of stomach, and that specifically &ldquo;rules out&rdquo; non-enteric coated conventional oral dosage forms such as tablets, capsules, or granules because they would degrade too quickly in stomach to be effective, nevertheless discloses, and does not &ldquo;teach away&rdquo; from, invention of asserted claims that encompass powder that can be combined with aqueous medium for oral administration, since reference teaches that uncoated omeprazole formulations containing sodium bicarbonate buffer could be used as alternative to enteric coating in order to protect omeprazole from degrading in stomach, and description of such formulation as &ldquo;second best&rdquo; is not clear discouragement such that it teaches away, and since reference's dosing regimen for suspensions of buffered, non-enteric coated omeprazole is not so complex that it teaches away from such formulations.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929787" href="#headnote_ref_pq2-dec_929787">[6]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnote_text">
Prior art reference that discloses dosing regimen for suspensions of buffered, non-enteric coated omeprazole to treat gastric acid disorders renders obvious certain claims of patents in suit directed to non-enteric coated solid pharmaceutical dosage forms, since reference teaches limitation requiring use of buffer in amount &ldquo;more than about 40 times&rdquo; amount of proton pump inhibitor (PPI) on weight-to-weight basis, and its use of 3360 mg of sodium bicarbonate meets limitation requiring &ldquo;at least&rdquo; 800 mg of sodium bicarbonate, and since reference teaches use of PPI and buffering agent in amounts and ratios recited in asserted claims; however, it would not have been obvious to person of ordinary skill in art to decrease amount of sodium bicarbonate buffer disclosed in prior art, since nothing in prior art indicates that it was ratio of buffering agent to PPI, rather than total amount of buffer consumed, that was viewed as key to preventing stomach from becoming too acidic, and thus asserted claims requiring amounts of buffering agent not disclosed in prior art are not invalid for obviousness.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_929788" href="#headnote_ref_pq2-dec_929788">[7]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Secondary considerations generally </span> <a href="http://www.bloomberglaw.com/document/1724924166147/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0907" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0907">&#9658;115.0907</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court did not clearly err in finding that patentee's objective evidence was insufficient to overcome obviousness of claims directed to formulations of benzimidazole proton pump inhibitors (PPIs) useful for treating stomach acid-related diseases and disorders, since district court expressly found that claimed formulations enjoyed no commercial success, citing evidence that sales of commercial embodiment of claimed invention were dwarfed by those of other PPIs and fell far short of patentee's expectations, since court found unpersuasive researcher's statement expressing skepticism that formulation would work, in that researcher was not witness subject to cross examination, and since court's findings of fact are entitled to deference, and there has been no showing that they were clearly erroneous.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of Delaware,
Gregory M. Sleet, Chief Judge.
<span CLASS="page_no" data-cite="694 f 3d 1345" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1345" data-primary-citation="694 F.3d 1344">[*1345]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="694 f 3d 1346" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1346" data-primary-citation="694 F.3d 1344">[*1346]</span> 
Morgan Chu, Irell &amp; Manella LLP, of Los Angeles, CA, argued for both
plaintiffs-appellants. With him on the brief for The Curators of the
University of Missouri were Jamison E. Lynch, Mayer Brown LLP, of Chicago,
IL. Of counsel for Santarus, Inc. were Gary N. Frischling and Joseph M.
Lipner, Irell &amp; Manella LLP, of Los Angeles, CA; and Andrea C. Hutchinson,
Mayer Brown LLP, of Chicago, IL, for The Curators of the University of
Missouri.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Janine A. Carian, Arent Fox, LLP, of Washington, DC, argued for
defendant-cross-appellant. On the brief was Richard J. Berman. Of counsel
were Timothy W. Bucknell, Aziz Burgy, Janine A. Carian, Joshua T. Morris,
Amy E.L. Schoenhard, and Anthony W. Shaw.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before RADER, Chief Judge, NEWMAN, and MOORE, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
PER CURIAM.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the court filed PER CURIAM. Opinion concurring in part and
dissenting in part filed by Circuit Judge NEWMAN.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appeal and cross-appeal are taken from the judgment of the United States
District Court for the District of Delaware.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> Plaintiff Santarus, Inc.
is the exclusive licensee of patents on specified formulations of
benzimidazole proton pump inhibitors (PPI) &mdash; a class of chemical compounds
that inhibit gastric acid secretion and help prevent and treat stomach
acid-related diseases and disorders. The patents are for the inventions of
Dr. Jeffrey Phillips, and are assigned to the University of Missouri.
Santarus provides the PPI product omeprazole in the formulations covered by
the Phillips patents, with the brand name Zegerid&reg;.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Defendant Par Pharmaceutical, Inc. filed an Abbreviated New Drug
Application (ANDA) for FDA approval to sell a generic counterpart of the
Santarus Zegerid&reg; products, invoking the Hatch-Waxman Act (the Drug Price
Competition and Patent Term Restoration Act of 1984), which established a
procedure called a "Paragraph IV certification,"
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(j)(2)(A)(vii)(IV), whereby an entity that seeks to market a
generic counterpart of a patented drug product or method of use, before the
patent has expired, may challenge the patent before actually marketing the
drug. Thus the parties are here litigating the issues of infringement,
validity, and enforceability of the Phillips patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Par's ANDA products infringe the Phillips
patents, but held all of the asserted claims invalid on the ground of
obviousness, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>. The court also held certain claims invalid on
the ground of inadequate
<span CLASS="page_no" data-cite="694 f 3d 1347" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1347" data-primary-citation="694 F.3d 1344">[*1347]</span> 
written description, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>. On the defense of unenforceability,
the district court held that there was not inequitable conduct by Dr.
Phillips, the University of Missouri, or their counsel in procuring <span CLASS="page_no" data-cite="2012 bl 224969 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> the
patents. Each side appeals the rulings adverse to it, except that Par does
not appeal the finding of infringement. We conclude that the district court
erred by holding that some of the thirty-six asserted claims would have been
obvious over the prior art; these rulings are reversed. The court's other
rulings are affirmed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I. THE PHILLIPS PATENTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Proton pump inhibitors affect the action of an enzyme within the stomach's
parietal cells, the cells within the membrane of the stomach that secrete
hydrochloric acid. It was known that chemicals of the class of
benzimidazoles <span CLASS="page_no" data-cite="104 uspq 2d 1644" data-cite-type="ReporterOfDecisions" data-cite-pageno="1644" data-primary-citation="104 U.S.P.Q.2d 1641">[**1644]</span> have the property of inhibiting or inactivating this proton
pump enzyme. The benzimidazoles operate by a mechanism whereby the
benzimidazole PPI, upon ingestion or intravenous infusion, circulates in the
bloodstream, from which it reaches and accumulates in the parietal cells and
affects the proton pump enzyme. Hydrochloric acid secretion does not recover
until the body produces a new quantity of the proton-producing enzyme.
Several benzimidazoles have been approved by the FDA for PPI use, including
products having the common names omeprazole (brand name Prilosec&reg;),
esomeprazole (Nexium&reg;), lansoprazole (Prevacid&reg;), rabeprazole (Aciphex&reg;),
and pantoprazole (Protonix&reg;).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although these PPIs are effective at blocking stomach acid production,
they are extremely acid-sensitive. It was known that unprotected PPIs in the
stomach's acidic environment do not survive long enough to be absorbed into
the bloodstream, and thus do not reach the parietal cells. To avoid this
destruction, PPI products for oral ingestion were provided with an
acid-resistant enteric coating, whereby the coated PPI passes safely through
the stomach to the intestine, where the coating dissolves and the PPI is
absorbed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Before Dr. Phillips's invention, all PPI products that were FDA-approved
for oral administration had an enteric coating. In contrast, the Phillips
products do not have an enteric coating. The products can be administered as
liquid suspensions of the solid uncoated PPI together with a buffering
agent, whereby the PPI is absorbed directly from the stomach into the
bloodstream. This formulation has the advantages of rapid and consistent
bioavailability and increased effectiveness, as well as ease of
administration to patients unwilling or unable to swallow capsules or
tablets. The Phillips patents explain:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      in their current form (capsules containing enteric-coated granules
    or enteric-coated tablets), proton pump inhibitors can be difficult
    or impossible to administer to patients who are either unwilling or
    unable to swallow tablets or capsules, such as critically ill
    patients, children, the elderly, and patients suffering from
    dysphagia.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%207,399,772&amp;summary=yes#jcite">U.S. Patent No. 7,399,772</a>, col.7 l.65-col.8 l.4. The Phillips products "can
alternatively be formulated as a powder, tablet, suspension tablet, chewable
tablet, capsule, effervescent powder, effervescent tablet, pellets and
granules." <i><cite>Id</cite>.</i> col.11 ll.50-53. The Phillips patents claim specific
combinations of the uncoated <span CLASS="page_no" data-cite="2012 bl 224969 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> benzimidazole PPI and buffering agents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par Pharmaceutical filed ANDA documents with the FDA, requesting
permission to market the same formulations as the Zegerid&reg; PPI, and
describing the Par products as bioequivalent to the Zegerid&reg; products
marketed by Santarus. Par asserted unenforceability of all of the claims of
the Phillips patents, and invalidity of the claims for which Santarus
charged Par with infringement: <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%206,489,346&amp;summary=yes#jcite">U.S. Patent No. 6,489,346</a> (the '<cite>346 patent</cite>)
<span CLASS="page_no" data-cite="694 f 3d 1348" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1348" data-primary-citation="694 F.3d 1344">[*1348]</span> 
claims 26, 37, 38, 49, 50, 58, 59, 60, 66, 68, 80, 81, 82; <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%207,399,772&amp;summary=yes#jcite">U.S. Patent No.
7,399,772</a> (the '<cite>772 patent</cite>) claims 1, 4, 5, 8, 10, 12, 14, 15, 20, 21; <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%206,780,882&amp;summary=yes#jcite">U.S.
Patent No. 6,780,882</a> (the '<cite>882 patent</cite>) claims 11, 12, 15, 27; <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%206,699,885&amp;summary=yes#jcite">U.S. Patent
No. 6,699,885</a> (the '<cite>885 patent</cite>) claims 2, 9, 11, 15, 16, 17, 18, 41; and
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%206,645,988&amp;summary=yes#jcite">U.S. Patent No. 6,645,988</a> (the '<cite>988 patent</cite>) claim 29.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Each of the Phillips patents is a continuation or continuation-in-part in
a chain that originated with <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=Patent%20No.%205,840,737&amp;summary=yes#jcite">Patent No. 5,840,737</a> (the '<cite>737 patent</cite>) based on
a provisional application filed on January 4, 1996. The '<cite>737 patent</cite>
describes the combination of the PPI and sodium bicarbonate, and states the
broadest claim as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. A method for treating gastric acid disorders by administering
    to a patient a single dose of a pharmaceutical composition of
    omeprazole or lansoprazole in a pharmaceutically acceptable carrier
    consisting essentially of a bicarbonate salt of a Group IA metal
    wherein said administering step consists of providing to the patient
    orally a single dose of an aqueous solution or, suspension of the
    pharmaceutical composition without requiring further administration
    of the bicarbonate salt of the Group IA metal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>737 patent</cite> claim 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '<cite>346 patent</cite> is a continuation-in-part of the '<cite>737 patent</cite>, with an
intervening abandoned application. Similar to the '<cite>737 patent</cite>, the '<cite>346
patent</cite> generally claims a method for treating an acid-caused
gastrointestinal disorder comprising administering a solid pharmaceutical
composition in a dosage form that is not enteric coated. <i>See, e.g.</i>, '<cite>346
patent</cite> claim 24. The dosage consists of PPI and a buffering agent, and the
claims specify certain ranges of PPI and buffer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '<cite>988 patent</cite> is a continuation-in-part of its predecessors. It includes
a new Figure 5 <span CLASS="page_no" data-cite="104 uspq 2d 1645" data-cite-type="ReporterOfDecisions" data-cite-pageno="1645" data-primary-citation="104 U.S.P.Q.2d 1641">[**1645]</span> showing the pH of gastroesophageal reflux disease and
discusses the scientific mechanism of operation of the PPI. Only claim 29 is
asserted. It recites a non-enteric coated solid oral pharmaceutical dosage
form comprising approximately 5-300 mg of PPI and a buffer in an amount of
0.1-2.5 mEq per mg of PPI. '<cite>988 patent</cite> claim 29. The dosage form also
includes a pharmaceutically-acceptable excipient, indicating that it is a
conventional dosage form such as a tablet, capsule, or granule. <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The other patents include additional limitations. For example, the '<cite>885
patent</cite> claims recite the serum concentration or blood level of PPI that is
obtained within 30 minutes after administration. <i>See, e.g.</i>, '<cite>885 patent</cite>
claim 2. The '<cite>882 patent</cite> claims a stable powder for suspension, having a
specified ratio of buffering agent to PPI, and a thickening agent. The
composition recited in the '<cite>772 patent</cite> contains no sucralfate. '<cite>772 patent</cite>
claim <span CLASS="page_no" data-cite="2012 bl 224969 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par argues that every asserted claim would have been obvious over any one
of several pieces of prior art. Par also argues that Dr. Phillips's own '<cite>737
patent</cite> renders obvious those claims to which it is prior art. Finally, Par
argues that all of the patents are unenforceable for inequitable conduct in
the Patent and Trademark Office. We start with the issue of inequitable
conduct, for this defense is asserted against all claims of all of the
patents in suit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II. INEQUITABLE CONDUCT
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par argues that all of the Phillips patents are unenforceable due to
inequitable conduct by Dr. Phillips, the University of Missouri, and their
attorneys, on the ground that they were tardy in informing the PTO that Dr.
Phillips had made the uncoated PPI formulation and administered it to some
hospital patients, and had informed medical colleagues and recorded the
medication and its test results in hospital
<span CLASS="page_no" data-cite="694 f 3d 1349" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1349" data-primary-citation="694 F.3d 1344">[*1349]</span> 
records, before the filing date of his first patent application. Par cites a
"Critical Care Abstract" written by Dr. Phillips at St. Vincent's Hospital,
entitled "The Effect of Omeprazole/Sodium Bicarbonate Solution
Administration on the Accuracy of subsequent pH Measurements Through the
Nasogastric Tube." This document reports his measurements of stomach acidity
for these formulations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par charged that this test information and report should have been
provided to the PTO during the prosecution of the first Phillips
application, instead of during the prosecution of the second, continuing
application. Par did not and does not argue that this information
invalidates any patent, but argues that the disclosure to the PTO should
have occurred during prosecution of the first-filed application, and that
failure to do so renders unenforceable all of the patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Phillips testified that he was unaware that his experimental
administration to patients and his measurement of the effect on stomach
acidity required disclosure to the PTO. He testified that he had believed
that only sale and public use were required to be disclosed, not
experimental development, and that he had not intentionally withheld
information or delayed its disclosure to the PTO. The University's patent
counsel testified that when he became aware of this test information he
provided it to the PTO by Information Disclosure Statement during
prosecution of the '<cite>346 application</cite>, which was the first continuing
application, for the first application had already issued as a patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par also stated that Dr. Phillips submitted a misleading declaration to
the PTO regarding a "Carroll Abstract," where, in response to an examiner's
rejection, Dr. Phillips submitted a declaration describing a test in which
he crushed enteric-coated PPI and mixed the crushed pellets with a sodium
bicarbonate solution; he declared that a suspension did not form, and
provided a photograph of the test tube containing the crushed pellets. Par
argued that Dr. Phillips distorted the study because he did not shake or
swirl the crushed pellets with the sodium bicarbonate solution. <span CLASS="page_no" data-cite="2012 bl 224969 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> Par's expert
testified that in his opinion it would take no more than five to ten minutes
for the shaken suspension to become homogeneous; this opinion was not
supported with evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929782" href="#headnote_pq2-dec_929782">[1]</a> The district court found that Par had shown materiality of some of this
information, and that the explanation by Dr. Phillips of why his test
information was not initially provided to the PTO "strained credibility."
However, the court also found that "the evidence presented is not sufficient
to establish by clear and convincing evidence that Dr. Phillips acted with
an affirmative intent to deceive." <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 461</a>. This
finding is in accord with <i>Therasense, Inc. v. Becton, Dickinson &amp; Co.</i>, where
this court explained that "[t]o prevail on a claim of inequitable <span CLASS="page_no" data-cite="104 uspq 2d 1646" data-cite-type="ReporterOfDecisions" data-cite-pageno="1646" data-primary-citation="104 U.S.P.Q.2d 1641">[**1646]</span> conduct,
the accused infringer must prove that the patentee acted with the specific
intent to deceive the PTO." <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">649 F.3d 1276</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FGJ4I003?jcsearch=649%20f%203d%201276&amp;summary=yes#jcite">1290</a> (Fed.Cir.2011) (en banc).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On this appeal Par stresses the district court's remark of "strained
credibility" and argues that this court should disbelieve Dr. Phillips, and
that the only reasonable inference is that he and his legal representatives
acted in bad faith and with intent to deceive. Santarus responds that the
district court did not find any testimony false, and that intent to deceive
was not established. We agree with the district court that intent to deceive
was not shown by clear and convincing evidence. The district court's ruling
that inequitable conduct was not established is affirmed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III. VALIDITY
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court invalidated the asserted claims of the '<cite>772 patent</cite> on
the ground
<span CLASS="page_no" data-cite="694 f 3d 1350" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1350" data-primary-citation="694 F.3d 1344">[*1350]</span> 
of inadequate written description and determined that the '772 claims are
not entitled to claim priority to the application that issued as the '<cite>737
patent</cite>. The court also invalidated all of the asserted claims on the ground
of obviousness over any of several prior art references. The court held that
the '<cite>737 patent</cite> rendered obvious every claim to which it is prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. WRITTEN DESCRIPTION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The written description issue relates to the inclusion of the clause
"wherein the composition contains no sucralfate" in the claims of the '<cite>772
patent</cite>. This limitation is present in the sole independent claim of the '<cite>772
patent</cite>, claim 1, which recites:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A method for treating an acid-caused gastrointestinal disorder
    comprising the step of administering to a subject suffering from
    said disorder a solid pharmaceutical composition comprising:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) about 10mg to about 40mg of nonenteric coated omeprazole; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (b) sodium bicarbonate in an amount of 0.2 mEq to 5 mEq per 2mg
    omeprazole;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      <i>wherein the composition contains no sucralfate</i>, the acid-caused
    gastrointestinal disorder is selected from the group consisting of
    duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and
    erosive esophagitis, and the sodium bicarbonate is present in the
    composition in an amount sufficient to substantially prevent or
    inhibit acid degradation of at least some of the omeprazole by
    gastric acid upon administration to the subject.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>772 patent</cite> claim 1 (emphasis added).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court held that it is necessary <span CLASS="page_no" data-cite="2012 bl 224969 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> for the '772 specification to
include evidence demonstrating that sucralfate is "contraindicated," in
order to meet the written description requirement of <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEIVVO003?jcsearch=35%20U.S.C.%20%20112&amp;summary=yes#jcite">&sect; 112</a> <cite>&para; 1</cite>. The court
held that it is inadequate that the specification states that Phillips's
claimed composition is "advantageous" as compared with sucralfate, a product
then commonly used to treat gastric ulcers and acid reflux. As a result, the
court found that neither the priority applications, such as the application
that issued as the '<cite>737 patent</cite>, nor the '772 specification support the "no
sucralfate" limitation. <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 444</a>. For the same
reasons, the court concluded that the asserted claims of the '<cite>772 patent</cite> are
not entitled to claim priority to the '<cite>737 patent</cite>'s filing date. <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929783" href="#headnote_pq2-dec_929783">[2]</a> The '772 specification states that "H2 antagonists, antacids, and
sucralfate . . . have certain disadvantages associated with their use. . . .
Proton pump inhibitors such as omeprazole represent an advantageous
alternative to the use of H2 antagonists, antacids, and sucralfate as a
treatment for complications related to stress-related mucosal damage." '<cite>772
patent</cite>, col.7 II.62-65. The district court held that this statement is
insufficient to meet the written description requirement, stating: "While
this indicates that omeprazole is preferable to sucralfate, the same
statements indicate with no less force that omeprazole is preferable to
antacids such as sodium bicarbonate. Nonetheless, sodium bicarbonate, an
ant-acid, is listed as the preferred carrier or buffer in the disclosed
invention. Thus it cannot be true that the priority applications' disclosure
of the disadvantages of sucralfate, by itself, implies that its use is
contraindicated." <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 443-44</a>. The district court held
that "consequently, the court finds that neither the priority applications
nor the specification of the '<cite>772 patent</cite> support the no sucralfate
limitation, for they do not show why a person of ordinary skill in the art
reading the application would believe that sucralfate was 'contraindicated'
in the claimed composition." <i></i><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20F.%20Supp.%202d%20427&amp;summary=yes#jcite">Id. at 444</a>.
<span CLASS="page_no" data-cite="104 uspq 2d 1647" data-cite-type="ReporterOfDecisions" data-cite-pageno="1647" data-primary-citation="104 U.S.P.Q.2d 1641">[**1647]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '<cite>737 patent</cite> specification states that sucralfate, "possibly the ideal
agent for
<span CLASS="page_no" data-cite="694 f 3d 1351" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1351" data-primary-citation="694 F.3d 1344">[*1351]</span> 
stress ulcer prophylaxis, [citing references]," was known to have occasional
adverse effects. '<cite>737 patent</cite>, col.3 ll.14-15, ll.25-27 ("[T]he only patient
whose death was attributed to stress-related upper gastrointestinal bleeding
was in the sucralfate arm. . . . "). Santarus argues that it is not
necessary to include in the specification evidence of "contraindication" of
sucralfate, and cites the testimony of Dr. Gilbert Banker, an expert witness
for Santarus, who testified that a person of ordinary skill in this field
would have known the properties and effects of sucralfate, and would have
understood from the specification that disadvantages of sucralfate may be
avoided by the Phillips formulation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We agree. The claim limitation specifying that sucralfate is not
administered in conjunction with the Phillips formulation restricted the
claims to this preferred use of the Phillips formulations. This exclusion
<span CLASS="page_no" data-cite="2012 bl 224969 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> narrowed the claims, as the patentee is entitled to do. The Manual of Patent
Examining Procedure explains that claims may state the exclusion of
alternatives. See MPEP <cite>&sect; 2173.05(i)</cite> ("If alternative elements are positively
recited in the specification, they may be explicitly excluded in the
claims."). For example, in <i>In re Johnson</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XIJ0QB?jcsearch=558%20f%202d%201008&amp;summary=yes#jcite">558 F.2d 1008</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XIJ0QB?jcsearch=558%20f%202d%201008&amp;summary=yes#jcite">1019</a> (CCPA 1977),
the applicant narrowed the claims to exclude the content of a lost
interference count, and the court observed that: "It is for the inventor to
decide what bounds of protection he will seek."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Negative claim limitations are adequately supported when the specification
describes a reason to exclude the relevant limitation. Such written
description support need not rise to the level of disclaimer. In fact, it is
possible for the patentee to support both the inclusion and exclusion of the
same material. The claim limitation that the Phillips formulations contain
no sucralfate is adequately supported by statements in the specification
expressly listing the disadvantages of using sucralfate. The district
court's holding that the '<cite>772 patent</cite> claims are invalid on written
description grounds is thus reversed. Because the lack of written
description for the "no sucralfate" limitation was the district court's only
reason for concluding that the '<cite>772 patent</cite> claims cannot claim priority to
the application that issued as the'<cite>737 patent</cite>, we also reverse this holding.
As a result, the '<cite>772 patent</cite> claims are entitled to claim priority to the
'<cite>737 patent</cite>, which thus cannot be used as prior art against them.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. OBVIOUSNESS &mdash; <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The primary issue on appeal is whether a solid dosage form of non-enteric
coated PPI such as omeprazole would have been obvious to one of ordinary
skill in the art. A patent is invalid for obviousness "if the differences
between the subject matter sought to be patented and the prior art are such
that the subject matter as a whole would have been obvious at the time the
invention was made to a person having ordinary skill in the art to which
said subject matter pertains." <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a). "Obviousness is a
question of law, which we review <i>de novo</i>, with underlying factual questions,
which we review for clear error following a bench trial." <i>Honeywell Int'l,</i>
<i>Inc. v. United States</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1DAEEM003?jcsearch=609%20f%203d%201292&amp;summary=yes#jcite">609 F.3d 1292</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1DAEEM003?jcsearch=609%20f%203d%201292&amp;summary=yes#jcite">1297</a> (Fed.Cir.2010). These underlying
factual inquires are: (1) the scope and content of the prior art; (2) the
differences between the prior art and the claims at issue; (3) the level of
ordinary skill in the field of the invention; and (4) objective
considerations such as commercial success, long felt need, and the failure
of others. <i>KSR Int'l Co., v. Teleflex, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">406</a>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007) (citing <i>Graham v. John Deere Co.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17-18</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966)). Patent invalidity
must be established by clear and convincing evidence.
<span CLASS="page_no" data-cite="694 f 3d 1352" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1352" data-primary-citation="694 F.3d 1344">[*1352]</span> 
<i>Microsoft Corp. v. i4i Ltd. P'ship</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">___ U.S. ___</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2242</a>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court held that the asserted claims would have been obvious
over several pieces of prior art. The scope and content of the prior art
applicable to each asserted claim, however, differs depending on the claim's
effective filing date. Due to breaks in the chain of priority, Santarus is
unable to claim an early enough priority date to preclude <span CLASS="page_no" data-cite="2012 bl 224969 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> use of Dr.
Phillips's own '<cite>737 patent</cite> as prior art for some of the asserted claims. In
a thorough analysis of priority, the district court determined that the '<cite>737
patent</cite> is prior art to claims 26, 37, 38, 49, 50, 66, 68, and 80-82 of the
'<cite>346 patent</cite> and the asserted claims of the '<cite>885 patent</cite>, '<cite>988 patent</cite>, and
'<cite>772 patent</cite>. <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 436-37</a>. Santarus appeals the court's
priority determination <i>only</i> as to the '<cite>772 patent</cite> (and as described above,
we reverse), and does not contend that the district <span CLASS="page_no" data-cite="104 uspq 2d 1648" data-cite-type="ReporterOfDecisions" data-cite-pageno="1648" data-primary-citation="104 U.S.P.Q.2d 1641">[**1648]</span> court erred by finding
that the '<cite>737 patent</cite> was prior art to the other claims. Accordingly,
Santarus waived any argument that the '<cite>737 patent</cite> is not prior art to the
other claims. <i>See Advanced Magnetic Closures, Inc. v. Rome Fastener Corp.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1DDN1O003?jcsearch=607%20f%203d%20817&amp;summary=yes#jcite">607 F.3d 817</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1DDN1O003?jcsearch=607%20f%203d%20817&amp;summary=yes#jcite">833</a> (Fed.Cir.2010). The asserted claims thus fall into one of
two categories depending on whether the '<cite>737 patent</cite> is prior art, and our
validity analysis must proceed on this basis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. Claims to Which the '<cite>737 Patent</cite> is Prior Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court correctly held that the '<cite>737 patent</cite> would have rendered
obvious all claims to which it is prior art. <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 452</a>.
The '<cite>737 patent</cite> is prior art to: claims 26, 37, 38, 49, 50, 66, 68, and
80-82 of the '<cite>346 patent</cite>; claims 2, 9, 11, 15-18, and 41 of the '<cite>885 patent</cite>;
and claim 29 of the '<cite>988 patent</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '<cite>737 patent</cite> discloses formulating omeprazole both in conventional
dosage forms (e.g., tablets, capsules, and granules) and also as an aqueous
suspension of omeprazole with a buffering agent. For example, the '<cite>737
patent</cite> discloses treating gastrointestinal conditions by administering:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A pharmaceutical composition for making a solution/suspension of
    omeprazole . . . includes omeprazole . . . and a bicarbonate salt of
    a Group 1A metal in a form for convenient storage whereby when the
    composition is dissolved in aqueous solution, the resulting solution
    is suitable for enteral administration.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>737 patent</cite> at [57].
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '<cite>737 patent</cite> discloses an example of such a suspension, which is formed
by mixing enteric coated omeprazole particles with a solution of water and
sodium bicarbonate. <i><cite>Id</cite>.</i> col.8 ll.6-41. Importantly, however, the '<cite>737 patent</cite>
teaches that the omeprazole does <i>not</i> need to be enterically coated. '<cite>737
patent</cite> col.8 ll.18-22 ("In a preferred embodiment of the present invention,
enterically-coated omeprazole particles are obtained from delayed release
capsules (Astra Merck) <i>additionally omeprazole powder can be used.</i>"
(emphasis added)). Even when examples use enteric coated omeprazole, the
'<cite>737 patent</cite> teaches that the sodium bicarbonate suspension "dissolves the
enteric coating" and emphasizes that "[i]t is important . . . that the
enteric coated pellets of omeprazole must be allowed to completely breakdown
in the suspension vehicle or carrier prior to administration." <i><cite>Id</cite>.</i> col.8
ll.21-28. The '<cite>737 patent</cite> also teaches that "[t]he omeprazole or other
substituted benzimidazoles and derivatives thereof and bicarbonate can be
formed into a tablet, capsules, or granules, by methods well known to those
skilled in the art." <i><cite>Id</cite>.</i> col.10 ll.29-33. While the prior art before the
'<cite>737 patent</cite> taught away from tablets, capsules, and granules
<span CLASS="page_no" data-cite="694 f 3d 1353" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1353" data-primary-citation="694 F.3d 1344">[*1353]</span> 
with non-enteric coated PPI, the '<cite>737 patent</cite> <span CLASS="page_no" data-cite="2012 bl 224969 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> expressly teaches these
formulations. The '<cite>737 patent</cite> thus discloses a solid dosage form within the
meaning of the asserted claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Santarus designates claims 2 and 17 as exemplary of the asserted claims of
the '<cite>885 patent</cite>. These claims depend from independent claim 1, which
recites:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A method of treating a gastric acid related disorder in a subject
    in need thereof, comprising:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      providing a solid pharmaceutical composition for oral
    administration to the subject, the composition consisting
    essentially of: (a) a therapeutically effective amount of at least
    one acid labile, substituted benzimidazole H<sup>+</sup>, K<sup>+</sup>-ATPase proton pump
    inhibitor; (b) <i>at least one buffering agent in an amount of about</i>
    <i>0.1 mEq to about 2.5 mEq per nig proton pump inhibitor</i>; and (c) one
    or more optional pharmaceutically acceptable excipients, wherein at
    least some of the proton pump inhibitor is not enteric coated and
    the solid pharmaceutical composition has a <i>total buffering agent to</i>
    <i>total proton pump inhibitor weight ratio of greater than 20:1</i>; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      orally administering the pharmaceutical composition to the
    subject, wherein upon oral administration of the pharmaceutical
    composition to the subject, <i>an initial serum concentration of the</i>
    <i>proton pump inhibitor greater than about 0.1 tig/ml is obtained at</i>
    <i>any time within about 30 minutes after administration</i> of the
    composition.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>885 patent</cite> claim 1 (emphases added). Claim 2 additionally requires an
initial serum concentration "greater than about 0.15 jig/ml at any time
within about 30 minutes after administration of the composition." <i><cite>Id</cite>.</i> claim
2. Claim 17 also requires that the buffering agent <span CLASS="page_no" data-cite="104 uspq 2d 1649" data-cite-type="ReporterOfDecisions" data-cite-pageno="1649" data-primary-citation="104 U.S.P.Q.2d 1641">[**1649]</span> be sodium bicarbonate "in
an amount from about 1000 mg to about 2000 mg." <i><cite>Id</cite>.</i> claim 17.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Santarus makes three arguments with regard to the '<cite>885 patent</cite> claims: (1)
they require an uncoated PPI and buffer in specific amounts and ratios not
disclosed in the prior art; (2) they achieve the desired results using only
1000 mg to 2000 mg of sodium bicarbonate; and (3) they achieve specific
blood serum concentration levels not disclosed in the prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929784" href="#headnote_pq2-dec_929784">[3]</a> Santarus is incorrect that the '<cite>737 patent</cite> fails to disclose non-enteric
coated PPIs and buffer within the claimed ratios. The '<cite>737 patent</cite> discloses
broad ranges for the amounts of omeprazole and sodium bicarbonate that can
be used, which overlap with the range of ratios of buffering agent to PPI
claimed in the '<cite>885 patent</cite>. For example, the '<cite>737 patent</cite> teaches that the
amount of sodium bicarbonate can vary between 0.75 mEq to 1.5 mEq per 2 mg
of omeprazole (0.375 to 0.75 mEq per mg of omeprazole). '<cite>737 patent</cite> col. 10
ll. 15-19. This falls within the range of about 0.1 mEq to about 2.5 mEq of
buffering agent per mg of PPI claimed in the '<cite>885 patent</cite>. Sodium bicarbonate
weighs roughly 84 mg/mEq, <i>see Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 441</a>, and thus the
range of buffering agent taught in the '737 patent equates to a weight ratio
of buffering agent to PPI of greater than 20:1 (i.e., 31.5-63 mg of sodium
bicarbonate per mg of PPI), as required by the claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '737 patent also discloses claim 17's limitation that the buffering
agent be sodium bicarbonate "<span CLASS="page_no" data-cite="2012 bl 224969 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> in an amount from about 1000 mg to about 2000
mg." The '737 patent teaches that the dosage range of non-enteric coated
omeprazole can vary from approximately 2 mg/day to 100 mg/day. '737 patent
col.9 ll.9-13. Because the ratio of sodium bicarbonate to PPI disclosed in
the '737 patent ranges from 0.75 mEq to 1.5 mEq per 2 mg of omeprazole, the
'737 patent teaches a range of 0.75-75 mEq of sodium bicarbonate. This range
<span CLASS="page_no" data-cite="694 f 3d 1354" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1354" data-primary-citation="694 F.3d 1344">[*1354]</span> 
equates to about 63-6300 mg of sodium bicarbonate, which overlaps with the
claimed range of 1000-2000 mg.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Santarus is also incorrect that the claims reciting specific blood serum
concentrations of PPI would have been nonobvious. The initial blood serum
concentration resulting from administering a PPI dosage is an inherent
property of the formulation, and an obvious formulation cannot become
nonobvious simply by administering it to a patient and claiming the
resulting serum concentrations. <i>See, e.g., In re Kao</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FEUP6003?jcsearch=639%20f%203d%201057&amp;summary=yes#jcite">639 F.3d 1057</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FEUP6003?jcsearch=639%20f%203d%201057&amp;summary=yes#jcite">1070</a>
(Fed.Cir.2011) ("[The prior art's] express teachings render the claimed . .
. formulation obvious, and the claimed [blood concentration] adds nothing of
patentable consequence."). To hold otherwise would allow any formulation &mdash;
no matter how obvious &mdash; to become patentable merely by testing and claiming
an inherent property. There is no dispute that the blood serum
concentrations claimed in the '<cite>885 patent</cite> are expected in light of the
dosages. In fact, a publication by Pilbrant and Cederberg entitled
"Development of an oral formulation of omeprazole" (Pilbrant) includes a
blood serum chart that indicates that the claimed levels are easily achieved
within the first thirty minutes after administration of a suspension of
non-enteric coated omeprazole buffered with sodium bicarbonate. J.A.
1315-16.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Santarus does not designate any of the other claims to which the '<cite>737
patent</cite> is prior art as being exemplary, nor does Santarus identify any other
specific limitations that are not disclosed in the prior art. We thus hold
that the district court correctly determined that claims 26, 37, 38, 49, 50,
66, 68, and 80-82 of the '<cite>346 patent</cite>, claims 2, 9, 11, 15-18, and 41 of the
'<cite>885 patent</cite>, and claim 29 of the '<cite>988 patent</cite> would have been obvious.<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  2. Claims to Which the '<cite>737 Patent</cite> is Not Prior Art
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The '<cite>737 patent</cite> is not prior art to claims 58-60 of the '<cite>346 patent</cite> or to
the asserted claims of the '882 and '772 patents. For these claims, the two
most relevant pieces of prior art are the Pilbrant reference and an article
by Lamers et al., entitled "Absorption of omeprazole in Zollinger-Ellison
syndrome is accelerated by alkali" (Lamers), J.A. 1464-65. The district
court held that Pilbrant and Lamers each individually render obvious every
asserted claim. <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 449</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties raise several issues relating to these prior art references.
They dispute whether, at the time of the Phillips invention, the prior art
taught away from the use of non-enteric coated oral dosage forms of PPIs.
The parties also disagree as to whether Pilbrant <span CLASS="page_no" data-cite="104 uspq 2d 1650" data-cite-type="ReporterOfDecisions" data-cite-pageno="1650" data-primary-citation="104 U.S.P.Q.2d 1641">[**1650]</span> and Lamers teach certain
limitations of the asserted claims and whether objective evidence justifies
a finding of nonobviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  a. Teaching Away <span CLASS="page_no" data-cite="2012 bl 224969 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> &mdash; The Solid Oral Dosage Limitation
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A reference "teaches away" when it "suggests that the line of development
flowing from the reference's disclosure is unlikely to be productive of the
result sought by the applicant." <i>Medichem, S.A. v. Rolabo, S.L.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X143KC2003?jcsearch=437%20f%203d%201157&amp;summary=yes#jcite">437 F.3d 1157</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X143KC2003?jcsearch=437%20f%203d%201157&amp;summary=yes#jcite">1165</a> (Fed. Cir.2006) (quoting <i>In re Gurley</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3MIHJ?jcsearch=27%20f%203d%20551&amp;summary=yes#jcite">27 F.3d 551</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3MIHJ?jcsearch=27%20f%203d%20551&amp;summary=yes#jcite">553</a>
(Fed.Cir.1994)). Whether a prior art reference teaches away from the claimed
invention is a question of fact. <i>Para-Ordnance Mfg., Inc. v. SGS Imps.</i>
<i>Int'l, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X4O297?jcsearch=73%20f%203d%201085&amp;summary=yes#jcite">73 F.3d 1085</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X4O297?jcsearch=73%20f%203d%201085&amp;summary=yes#jcite">1088</a> (Fed.Cir.1995).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Santarus argues that the prior art, particularly Pilbrant, taught away
from the claimed invention. Specifically, Santarus
<span CLASS="page_no" data-cite="694 f 3d 1355" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1355" data-primary-citation="694 F.3d 1344">[*1355]</span> 
contends that the dosing regimen Pilbrant discloses for suspensions of
buffered nonenteric coated omeprazole was so complex that it would
discourage a person of ordinary skill in the art from pursuing such
formulations. Santarus argues that this, coupled with the fact that Pilbrant
expressly "ruled out" non-enteric coated tablets, capsules, and granules,
would discourage a skilled artisan from using <i>any</i> nonenteric coated oral
dosage forms of PPIs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929785" href="#headnote_pq2-dec_929785">[4]</a> Santarus is partly correct. Pilbrant teaches that the options for
formulating omeprazole are limited because it is minimally soluble in water
but degrades rapidly in the acidic environment of the stomach. J.A. 1313.
Pilbrant discusses four options: 1) solutions; 2) suspensions of buffered
non-enteric coated omeprazole; 3) conventional oral doeage forms &mdash; tablets,
capsules or granules &mdash; with nonenteric coated PPIs; and 4) conventional oral
dosage forms with enteric-coated PPIs. J.A. 1313-14. Pilbrant states that
the fourth option, conventional dosage forms with enteric-coated PPIs,
"offers the best possibilities." J.A. 1314. Pilbrant explicitly "ruled out"
the third option &mdash; non-enteric coated conventional oral dosage forms such as
tablets, capsules, or granules &mdash; because they degrade too quickly in the
stomach to be absorbed in sufficient amounts to be effective. J.A. 1313.
This disclosure would discourage a person of ordinary skill in the art from
pursuing <i>conventional oral dosage forms</i> such as tablets, capsules, or
granules with non-enteric coated PPIs, and thus teaches away from such
formulations. As a result, we hold that the district court erred by
concluding that claims directed to such conventional dosage forms would have
been obvious over Pilbrant or Laniere. We thus reverse the court's
obviousness holding with respect to claims 4, 5, 8, 10, 12, 14, and 15 of
the '<cite>772 patent</cite>, which all are directed to conventional dosage forms, such
as tablet or capsules, containing non-enteric coated PPIs.<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929786" href="#headnote_pq2-dec_929786">[5]</a> Santarus is incorrect, however, that the prior art taught away from <i>all</i>
non-enteric coated omeprazole formulations. The district court broadly
construed the claim terms "solid pharmaceutical composition in a dosage
form" and "solid oral pharmaceutical dosage form" as "including a powder
that can be combined with an aqueous medium then orally administered." J.A.
300. As a result of these undisputed constructions, many of the asserted
claims cover powder formulations for use in aqueous suspensions. The prior
art does not teach away from such <span CLASS="page_no" data-cite="2012 bl 224969 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> powder formulations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the district court found, "[t]he Lamers and Pilbrant references teach
that <i>un-coated omeprazole formulations</i> containing a sodium bicarbonate
buffer could be used as an alternative to enteric coating in order to
protect omeprazole from degrading in the stomach." <i>Santarus</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 448-49</a> (emphasis added). Although Pilbrant "ruled out"
conventional dosage forms such as tablets, capsules, or granules with
non-enteric coated PPIs, it states that a "rapidly dissolving suspension of
micronized omeprazole is the <i>second best choice</i> as the reference
formulation." J.A. 1315 (emphasis added). As Par's expert testified,
Pilbrant also teaches that such buffered suspensions using nonenteric coated
omeprazole have a similar effect on gastric acid secretion as enteric coated
omeprazole without bicarbonate. J.A. 1316; J.A. 1130-31.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pilbrant thus teaches that, although sus-pensions of buffered non-enteric
coated
<span CLASS="page_no" data-cite="694 f 3d 1356" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1356" data-primary-citation="694 F.3d 1344">[*1356]</span> 
omeprazole may be the "second best choice," they are a viable alternative to
enteric coating. "A <span CLASS="page_no" data-cite="104 uspq 2d 1651" data-cite-type="ReporterOfDecisions" data-cite-pageno="1651" data-primary-citation="104 U.S.P.Q.2d 1641">[**1651]</span> statement that a particular combination is not a
preferred embodiment does not teach away absent clear discouragement of that
combination." <i>Syntex (U.S.A.) LLC v. Apotex, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X12A4J0003?jcsearch=407%20f%203d%201371&amp;summary=yes#jcite">407 F.3d 1371</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X12A4J0003?jcsearch=407%20f%203d%201371&amp;summary=yes#jcite">1380</a>
(Fed.Cir.2005). Describing a formulation as "second best" is not a "clear
discouragement," as is required by our precedent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nor do we see any merit to Santarus's contention that the dosing regimen
Pilbrant discloses for suspensions of buffered non-enteric coated omeprazole
was so complex that it taught away from such formulations. Pilbrant teaches
that a total of 40 mmoles of sodium bicarbonate should be given with 250 mL
of water in five divided doses after a ten-hour overnight fast, J.A. 1315.
The district court did not clearly err by declining to find that this
regimen, which basically requires dissolving less than half a teaspoon of
sodium bicarbonate in just over a cup of water, is such a strain on patient
compliance as to teach away from using a buffered suspension of nonenteric
coated omeprazole. <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 447-48</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, Pilbrant discloses, and does not teach away from, "a powder that can
be combined with an aqueous medium then orally administered." For the claims
that are broad enough to include this powder (i.e., those not limited to
tablets, capsules, or granules), the solid pharmaceutical dosage limitation
is taught by Pilbrant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  b. Other Claim Limitations
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The thrust of this appeal is whether the prior art discloses the claimed
nonenteric coated solid pharmaceutical dosage forms. In cursory form,
Santarus argues a limited number of additional limitations that it alleges
are not present in the prior art, such as the claimed amounts and ratios of
PPI and buffer. We conclude that the district court was correct that claims
58-60 of the '<cite>346 patent</cite> and claims 12 and 27 of the '<cite>882 patent</cite> would have
been obvious over Pilbrant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Santarus contends that Pilbrant and Lamers fail to teach a dosage with PPI
and buffer in the amounts and ratios recited in claim 60 of the '<cite>346 patent</cite>,
which Santarus designated as an exemplary claim. Claim 60 of the '<cite>346 patent</cite>
depends from claim 57, <span CLASS="page_no" data-cite="2012 bl 224969 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> which recites:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A solid pharmaceutical composition in a dosage form that is not
    enteric-coated, comprising: active ingredients consisting
    essentially of:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) a therapeutically effective amount of a non-enteric coated
    proton pump inhibitor selected from the group consisting of
    omeprazole, lansoprazole, rabeprazole, esbmeprazole, pantoprazole,
    pariprazole, and leminoprazole, or an enantiomer, isomer,
    derivative, free base, or salt thereof; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (b) a buffering agent selected from the group consisting of sodium
    bicarbonate, and calcium carbonate, in an amount more than about 40
    times the amount of the proton pump inhibitor on a weight to weight
    basis in the composition.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>346 patent</cite> claim 57. Claim 60 further requires that the buffering agent be
sodium bicarbonate in an amount of at least 800 mg. <i><cite>Id</cite>.</i> claim 60.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929787" href="#headnote_pq2-dec_929787">[6]</a> As the district court found, Pilbrant discloses administering
approximately 3360 mg of sodium bicarbonate with 60 mg of omeprazole, a
ratio of 56:1 on a weight to weight basis. <i>See Santarus</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 447</a>. Pilbrant thus teaches the limitation of using an
amount of buffer "more than about 40 times the amount of proton pump
inhibitor on a weight to weight basis." Pilbrant's use of 3360 mg of sodium
bicarbonate also meets claim 60's limitation of using "at least about 800
mg" of sodium
<span CLASS="page_no" data-cite="694 f 3d 1357" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1357" data-primary-citation="694 F.3d 1344">[*1357]</span> 
bicarbonate. Pilbrant similarly teaches using PPI and buffering agent in the
amounts and ratios recited in claims 58-59 of the '<cite>346 patent</cite> and claims 12
and 27 of the '<cite>882 patent</cite>. Thus we find no merit in the arguments related to
these claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Exemplary claims 20 and 21 of the '<cite>772 patent</cite>, however, require amounts of
buffering agent not disclosed in the prior art. Claim 20 requires 2-25 mEq
of sodium bicarbonate buffer while claim 21 requires 4-25 mEq of sodium
bicarbonate. '<cite>772 patent</cite> claims 20, 21. Pilbrant discloses using 40 mEq
(3360 mg) of sodium bicarbonate, which is significantly more than the amount
claimed in the '<cite>772 patent</cite>. J.A. 1315. Par appears to contend that, because
Pilbrant and Lamers both teach the claimed ratio of sodium bicarbonate to
PPI, it would have been obvious to a person of ordinary skill in the art to
reduce the total amount of sodium bicarbonate buffer disclosed in those
references. <i>See, e.g.</i>, Cross-Appellant's Br. 19-20. Par, however, failed to
establish <span CLASS="page_no" data-cite="104 uspq 2d 1652" data-cite-type="ReporterOfDecisions" data-cite-pageno="1652" data-primary-citation="104 U.S.P.Q.2d 1641">[**1652]</span> this by clear and convincing evidence. Pilbrant states that the
purpose of consuming sodium bicarbonate with the omeprazole solution was to
"buffer the pH of the gastric content to neutral values." J.A. 1315. Par
points to nothing in the prior art that indicates it was the ratio of
buffering agent to PPI, as opposed to the total amount of buffer consumed,
that was the key to preventing the stomach from being too acidic. Given the
prior art's teachings regarding protecting omeprazole from stomach acid, we
hold that it would not have been obvious to a person of ordinary skill in
the art to decrease the amount of sodium bicarbonate disclosed in Lamers or
Pilbrant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Likewise, the required amount of buffering agent in claims 11 and 15 of
the '<cite>882 patent</cite> are not disclosed by Pilbrant or Lamers. Claim 11 requires
an <span CLASS="page_no" data-cite="2012 bl 224969 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> amount of buffering agent of about 15-30 mEq. '<cite>882 patent</cite> claim 11. Claim
15 requires about 12.5-30 mEq of sodium bicarbonate buffer. <i><cite>Id</cite>.</i> claim 15. As
a result, we reverse this portion of the district court judgment and hold
that Par did not establish by clear and convincing evidence that these
claims would have been obvious over Pilbrant or Lamers.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  c. Objective Considerations
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_929788" href="#headnote_pq2-dec_929788">[7]</a> Santarus argues that the district court's fact findings regarding
objective evidence were clearly erroneous. Santarus cites the testimony of
its expert Dr. Fennerty that skepticism in the industry, unexpected results,
long-felt need, industry recognition, and commercial success support a
holding of nonobviousness. Appellant's Br. 50-53. Santarus also cites a
statement by researcher Dr. George Sachs expressing his skepticism that
Zegerid&reg; would work. <i></i><cite>Id. at 11-12</cite>. The district court, however, reviewed all
of the secondary consideration evidence and concluded that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The evidence in the record on several relevant secondary
    considerations does not undermine the court's finding that the
    patent is obvious in light of the prior art. On the contrary, the
    weight of the evidence as to the relevant secondary considerations
    confirms the court's finding in this regard.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 453</a>. The court expressly found that there was no
commercial success. <i></i><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20F.%20Supp.%202d%20427&amp;summary=yes#jcite">Id. at 453-55</a>. For example, the court found that sales
of Zegerid&reg; were dwarfed by those of other PPIs and "fell far short of
Santarus' own expectations." <i></i><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20F.%20Supp.%202d%20427&amp;summary=yes#jcite">Id. at 453-54</a>. The court also rejected
Santarus's arguments with respect to the other objective factors. <i></i><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20F.%20Supp.%202d%20427&amp;summary=yes#jcite">Id. at
455-59</a>. For example, the district court found the statement by Dr. Sachs
unpersuasive for several reasons, including that Dr. Sachs was not a witness
at trial and
<span CLASS="page_no" data-cite="694 f 3d 1358" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1358" data-primary-citation="694 F.3d 1344">[*1358]</span> 
thus was not subject to cross examination. <i></i><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20F.%20Supp.%202d%20427&amp;summary=yes#jcite">Id. at 456</a>. The district court's
findings of fact are entitled to deference, and San taras failed to show
that they are clearly erroneous. <i>See, e.g., Para-Ordnance Mfg., Inc.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X4O297?jcsearch=73%20f%203d%201085&amp;summary=yes#jcite">73 F.3d at 1091</a>. We thus hold that Santarus's objective evidence is
insufficient to overcome the obviousness of the claims over Pilbrant. We
thus affirm the district court's conclusion that claims 12 and 27 of the
'<cite>882 patent</cite> and claims 58-60 of the '<cite>346 patent</cite> would have been obvious over
Pilbrant and reverse the court's holding that claims 11 and 15 of the '<cite>882
patent</cite> claims 20 and 21 of the '<cite>772 patent</cite> would have been obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  IV. SUMMARY
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In view of the foregoing, we affirm the district court's ruling that Par
failed to establish inequitable conduct. We also affirm the court's
determination that the following claims would have been obvious over the
prior art: claims 12 and 27 of the '<cite>882 patent</cite>; claims 26, 37, 38, 49, 50,
58-60, 66, 68, and 80-82 of the '<cite>346 patent</cite>; claims 2, 9, 11, 15-18, and 41
of the '<cite>885 patent</cite>; and claim 29 of the '<cite>988 patent</cite>. We reverse the district
court's ruling that the asserted claims of the '<cite>772 patent</cite> and claims 11 and
15 of the '<cite>882 patent</cite> would have been obvious. We also reverse the district
court's holding that the claims of the '<cite>772 patent</cite> are invalid for lack of
written description. We remand for further proceedings consistent with <span CLASS="page_no" data-cite="2012 bl 224969 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> this
opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED-IN-PART, REVERSED-IN-PART, and REMANDED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> <i>Santarus, Inc. v. Par Pharm., Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d 427</a> (D.Del.2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> For the same reasons discussed in <cite>section 2</cite>.C., <i>infra</i>, the district
court's fact findings regarding objective considerations are not clearly
erroneous.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Claims 4 and 5 of the '<cite>772 patent</cite> are not expressly limited to a
tablet or capsule dosage form, but require specific pharmaceutical
excipients (disintegrants and lubricants) that are commonly used in
conventional dosage forms such as tablets, not in powder formulations.
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  NEWMAN, Circuit Judge, concurring in part, dissenting in part.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I agree that inequitable conduct has not been shown. However, the court
errs in three major areas, misconstruing established law. First, the court
creates a new "written description" requirement for limitations in claims, a
requirement with important consequences for patent content and prosecution,
and that will taint large numbers of issued patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority also holds that the disclosure in a parent patent is a
reference <span CLASS="page_no" data-cite="104 uspq 2d 1653" data-cite-type="ReporterOfDecisions" data-cite-pageno="1653" data-primary-citation="104 U.S.P.Q.2d 1641">[**1653]</span> against the common disclosure in a continuation-in-part patent,
again tainting many properly granted patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority also holds that most of the claims in suit are invalid
on the ground of obviousness over references that explicitly teach away from
the inventions in the Phillips patents. In the district court, the experts
for both sides agreed that for oral dosage of PPIs the protective enteric
coating was understood to be essential. Only the panel majority finds that
the extreme conditions that the prior art deemed necessary for oral dosage
of un-coated PPIs, would be acceptable for patient treatment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The court's new rulings are contrary to statute, precedent, and common
sense. They simply add to the unreliability of duly granted patents, in new
and unacceptable ways.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  WRITTEN DESCRIPTION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The claims of the '<cite>772 patent</cite> (<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%207,399,772&amp;summary=yes#jcite">U.S. Patent No. 7,399,772</a>) contain the
limitation that these uncoated PPI formulations do not contain the known
therapy sucralfate. I agree that the district court clearly erred in finding
that since the specification did not contain evidence of "contraindication"
of sucralfate, the patent failed the written description requirement. On
appellate review, correction of this erroneous finding is all that is
needed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, my colleagues add a gratuitous fillip, and devise the new rule
that the specification must "describe a reason" for the claim limitation, or
the claims are invalid on written description grounds.
<span CLASS="page_no" data-cite="694 f 3d 1359" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1359" data-primary-citation="694 F.3d 1344">[*1359]</span> 
Maj. op. at 1351 ("Negative claim limitations are adequately supported when
the specification describes a reason to exclude the relevant limitation.").
That is not correct. Negative claim limitations may often be appropriately
stated in claims although the reason for the limitation is not set forth in
the specification.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Negative limitations to claims may arise in a variety of circumstances.
For example, a negative limitation may be prudently placed in a claim in
response to an examiner's rejection, perhaps to distinguish a reference that
was given its "broadest reasonable interpretation" for purposes of
examination. <i>See, e.g., In re Skvorecz</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1BLN4U003?jcsearch=580%20f%203d%201262&amp;summary=yes#jcite">580 F.3d 1262</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1BLN4U003?jcsearch=580%20f%203d%201262&amp;summary=yes#jcite">1268</a> (Fed.Cir.2009)
("Applicant always has the opportunity to amend the claims during
prosecution, and broad interpretation by the examiner reduces the
possibility that the claim, once issued, will be interpreted more broadly
than is justified." (quoting Manual of Patent Examining Procedure (MPEP) <cite>&sect;
2111</cite>)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A claim limitation may distinguish the prior art although the reason is
not in the specification. Claims are routinely adjusted during prosecution
<span CLASS="page_no" data-cite="2012 bl 224969 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> in the Patent and Trademark Office. As stated in <i>In re Johnson</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XIJ0QB?jcsearch=558%20f%202d%201008&amp;summary=yes#jcite">558 F.2d 1008</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XIJ0QB?jcsearch=558%20f%202d%201008&amp;summary=yes#jcite">1018</a> (CCPA 1977), "applicants frequently discover during the
course of prosecution that only a part of what they invented and originally
claimed is patentable." This adjustment may include limitations that respond
to the prior art developed by the examiner and traversed by the applicant.
The specification need not foresee and describe the reason for every
possible examination response.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As another example of routine patent procedures, there may be situations
in which comparative data are provided during prosecution in order to
respond to an examiner's rejection, <i>see</i> MPEP &sect; 716, and the distinction from
the prior art may lead to a claim limitation. The need for the limitation
may not have been apparent when writing the specification. For example, in
<i>In re Johnson, supra</i>, the court held that the claims could be limited during
prosecution in order to avoid subject matter lost in an interference; the
court explained that: "It is for the inventor to decide what bounds of
protection he will seek." <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XIJ0QB?jcsearch=558%20f%202d%201008&amp;summary=yes#jcite">558 F.2d at 1018</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The applicant's obligation is to describe and claim the invention in
accordance with <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>. Thereafter, patent examination may lead to
amendments to the claims. The MPEP <cite>&sect; 2173.05(i)</cite> advises that: "If
alternative elements are positively recited in the specification, they may
be explicitly excluded in the claims." The MPEP does not require that the
reason for such exclusion must be stated in the specification. The panel
majority creates a new and far-reaching ground of invalidity, a ground that
received no deliberation and advice from the concerned communities.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Further, this new requirement for patent specifications is not an issue in
this case, for the '772 specification states that sucralfate, "possibly the
ideal agent for stress ulcer prophylaxis, [citing references]," is known to
have occasional adverse effects, and that "the only patient whose death was
attributed to <span CLASS="page_no" data-cite="104 uspq 2d 1654" data-cite-type="ReporterOfDecisions" data-cite-pageno="1654" data-primary-citation="104 U.S.P.Q.2d 1641">[**1654]</span> stress-related upper gastrointestinal bleeding was in the
sucralfate arm." '<cite>772 patent</cite>, col.4 ll.1-29. Thus the reason for excluding
sucralfate was indeed stated in the specification. Nonetheless, the district
court held that evidence of "contraindication" of sucralfate was required.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I agree with the panel majority that the Phillips invention was adequately
described, and that the district court erred in its requirement. "Compliance
with the written description requirement is essentially a fact-based inquiry
that will 'necessarily vary depending on the nature of the
<span CLASS="page_no" data-cite="694 f 3d 1360" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1360" data-primary-citation="694 F.3d 1344">[*1360]</span> 
invention claimed.'" <i>Enzo Biochem v. Gen-Probe, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XANMKG?jcsearch=296%20f%203d%201316&amp;summary=yes#jcite">296 F.3d 1316</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XANMKG?jcsearch=296%20f%203d%201316&amp;summary=yes#jcite">1324</a>
(Fed.Cir.2002) (citation omitted). The panel majority is incorrect in its
new general requirement that the reason for any negative limitation must be
included in the specification, on pain of invalidity under <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEIVVO003?jcsearch=35%20U.S.C.%20%20112&amp;summary=yes#jcite">&sect; 112</a>. This new
ground of invalidity ignores the factual nature of the written description
requirement, and impugns the presumption of validity of a duly granted
patent. The court's new rule simply adds to the uncertainty of the patent
grant, to the detriment of invention and commerce.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  THE <span CLASS="page_no" data-cite="2012 bl 224969 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> PARENT PATENT AS PRIOR ART
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority creates another new ground of invalidity, in holding
that the common disclosure in a parent patent is prior art to the chain of
continuing patents. The court incorrectly holds that the parent '<cite>737 patent</cite>
(<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%205,840,737&amp;summary=yes#jcite">U.S. Patent No. 5,840,737</a>) that issued to Dr. Phillips is an invalidating
reference based on the common subject matter that has priority to the parent
patent's filing date.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The claims at issue all include subject matter disclosed in the '<cite>737
patent</cite>, subject matter for which priority was properly claimed, with no
breaks in the chain of filings. It is beyond debate that the common subject
matter in a chain of copending applications is entitled to priority from the
earliest application disclosing the common subject matter. <i>See, e.g.</i>,
Herbert F. Schwartz &amp; Robert J. Goldman, <i>Patent Law &amp; Practice</i> <cite>&sect; 2.III.D.7</cite>.C
(6th ed. 2008) ("A continuation-in-part is entitled to the parent's filing
date as to any subject matter in common, but only to its own filing date as
to the new matter."); James E. Hawes, <i>Patent Application Practice</i> <cite>&sect; 18:5.50</cite>
(Rel.27, 2011) ("The parent's filing date will apply to all the material in
the child [CIP] that was in the parent, but the new material will not be
accorded the benefit of the parent's filing date."); Irah H. Donner, <i>Patent</i>
<i>Prosecution: Law, Practice, and Procedure</i> 156 (7th ed. 2011) ("The CIP
application priority date is the same as that of the earlier-filed
application for subject matter common to the two applications.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Ignoring this basic tenet of patent law, the panel majority uses the
common subject matter from the '<cite>737 patent</cite> to invalidate many of the
claims-in-suit. The panel majority describes this common subject matter at
length, but instead of understanding that the common subject matter supports
the claims that are entitled to the priority of that subject matter, the
panel majority holds that the common subject matter invalidates the claims
to that subject matter.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For example, the panel majority goes into detail for the '<cite>885 patent</cite> (<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%206,699,885&amp;summary=yes#jcite">U.S.
Patent No. 6,699,885</a>), ruling that because the claims in the '<cite>885 patent</cite> are
supported by the common subject matter in the parent <cite>737 patent</cite>, the claims
in the <cite>'885</cite> are rendered obvious by the parent '<cite>737 patent</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Priority lor the '<cite>885 patent</cite> was properly claimed, in accordance with
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEJ008003?jcsearch=35%20usc%20120&amp;summary=yes#jcite">35 U.S.C. &sect; 120</a>, as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      This application is a continuation-in-part of U.S. <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=patent%20application%20Ser.%20No.%2009/901,942&amp;summary=yes#jcite">patent
    application Ser. No. 09/901,942</a>, filed on Jul. 9, 2001, which is a
    continuation-in-part of U.S. <cite>patent application Ser. No. 09/481,207</cite>,
    filed on Jan. 11, 2000, now <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Pat.%20No.%206,489,346&amp;summary=yes#jcite">U.S. Pat. No. 6,489,346</a>, which is a
    continuation-in-part of U.S. <cite>patent application Ser. No. 09/183,422</cite>,
    filed on Oct. 30, 1998, now abandoned, which is a
    continuation-in-part of U.S. patent application Ser. No.
    08/680,-376, filed on Jul. 15, 1996, now <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X2I0G071HOJ?jcsearch=U.S.%20Pat.%20No.%205,840,737&amp;summary=yes#jcite">U.S. Pat. No. 5,840,737</a>,
    which claims priority to U.S. Provisional Application Ser. No.
    60/009,608 filed on Jan. 4, 1996. This application claims priority
    to all such
<span CLASS="page_no" data-cite="694 f 3d 1361" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1361" data-primary-citation="694 F.3d 1344">[*1361]</span> 
    previous applications, and such applications are hereby incorporated
    herein by reference.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<cite>'885 patent</cite>, col.1 ll.4-16. There is no break in the chain of priority. The
panel majority correctly observes that the <cite>737 patent</cite><span CLASS="page_no" data-cite="2012 bl 224969 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span>  describes the subject
matter claimed in the <cite>'885 patent</cite>. The <cite>737 patent</cite> describes the combination
of the PPI and a Group IA metal salt, as follows:
<span CLASS="page_no" data-cite="104 uspq 2d 1655" data-cite-type="ReporterOfDecisions" data-cite-pageno="1655" data-primary-citation="104 U.S.P.Q.2d 1641">[**1655]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The present invention further includes a pharmaceutical
    composition for making a solution/suspension of omeprazole or other
    substituted benzimidazoles and derivatives thereof, which consists
    essentially of omeprazole or other substituted benzimidazoles and
    derivatives thereof and a bicarbonate salt of a Group IA metal in a
    form convenient for storage, whereby when the composition is placed
    into a aqueous solution, the composition dissolves yielding a
    solution/suspension suitable for enteral administration to a
    subject. The pharmaceutical composition is in a solid form prior to
    dissolution in the aqueous solution. The omeprazole or other
    substituted benzimidazoles and derivatives thereof and bicarbonate
    can be formed into a tablet, capsule, or granules, by methods well
    known to those skilled in the art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>737 patent</cite>, col.10, 11.20-33. The panel majority explains that the '885
subject matter is disclosed in the <cite>737 patent</cite>, stating: "The <cite>737 patent</cite>
discloses broad ranges for the amounts of omeprazole and sodium bicarbonate
that can be used, which overlap with the range of ratios of buffering agent
to PPI claimed in the <cite>'885 patent</cite>." Maj. op. at 1353. The panel majority
states that the "<cite>737 patent</cite> discloses formulating omeprazole both in
conventional dosage forms (e.g., tablets, capsules, and granules) and also
as an aqueous suspension of omeprazole with a buffering agent," as claimed
in the <cite>'885 patent</cite>. Maj. op. at 1352. The panel majority states that "the
<cite>737 patent</cite> teaches that the amount of sodium bicarbonate can vary between
0.75 mEq to 1.5 mEq per 2 mg of omeprazole (0.375 to 0.75 mEq per mg of
omeprazole)," and observes that "this falls within the range of about 0.1
mEq to about 2.5 mEq of buffering agent per mg of PPI claimed in the <cite>'885
patent</cite>." Maj. op. at 1353.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Focusing on claim 17 of the <cite>'885 patent</cite>, the panel majority states that:
"The <cite>737 patent</cite> also discloses claim 17's limitation that the buffering
agent be sodium bicarbonate 'in an amount from about 1000 mg to about 2000
mg'." The panel majority points to where the 737 disclosure shows the claim
17 dosage range of uncoated omeprazole, and where "the <cite>737 patent</cite> teaches a
range of 0.75-75 mEq of sodium bicarbonate, which overlaps with the claimed
range [in the <cite>'885 patent</cite>]." Maj. op. at 1353-54. The panel majority
illustrates and stresses that the subject matter of claim 17 is within the
<cite>737 patent</cite>'s disclosure.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority forgets that "matter disclosed in the parent
application is entitled to the benefit of the filing date of the parent
application." <i>Waldemar Link, GmbH &amp; Co. v. Osteonics Corp.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3906C?jcsearch=32%20f%203d%20556&amp;summary=yes#jcite">32 F.3d 556</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3906C?jcsearch=32%20f%203d%20556&amp;summary=yes#jcite">558</a>
(Fed.Cir.1994); <i>see Litton Sys., Inc. v. Whirlpool Corp.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X39TCG?jcsearch=728%20f%202d%201423&amp;summary=yes#jcite">728 F.2d 1423</a>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X39TCG?jcsearch=728%20f%202d%201423&amp;summary=yes#jcite">1438</a> (Fed.Cir.1984) ("The earlier filing date of the parent application
pertains to material in the C-I-P application also disclosed in the prior
application. <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEJ008003?jcsearch=35%20usc%20120&amp;summary=yes#jcite">35 U.S.C. &sect; 120</a>."). Instead, the panel majority relies upon the
common subject matter from the <cite>737 patent</cite> disclosure to invalidate the '885
claims supported by that subject matter. <span CLASS="page_no" data-cite="2012 bl 224969 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> This is incorrect, for the common
subject matter in the '<cite>885 patent</cite> is entitled to the 737 filing date. That
entitlement is not lost by issuance of the <cite>737 patent</cite>. The common subject
matter, properly carried forward in copending continuing
<span CLASS="page_no" data-cite="694 f 3d 1362" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1362" data-primary-citation="694 F.3d 1344">[*1362]</span> 
patents, cannot be prior art against itself, as the majority holds.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Similarly, the '<cite>988 patent</cite> (<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X31GGA9420J?jcsearch=U.S.%20Patent%20No.%206,645,988&amp;summary=yes#jcite">U.S. Patent No. 6,645,988</a>) states the chain of
copendency, and incorporation by reference, as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      This application is a continuation-in-part of U.S. <cite>patent
    application Ser. No. 09/481,207</cite> filed Jan. 11, 2000, now <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3110I321GJ?jcsearch=U.S.%20Pat.%20No.%206,489,346&amp;summary=yes#jcite">U.S. Pat.
    No. 6,489,346</a> which is a continuation-in-part of U.S. <cite>patent
    application Ser. No. 09/183,422</cite> filed on Oct. 30, 1998, now
    abandoned, which is a continuation-in-part of U.S. <cite>patent
application Ser. No. 08/680,376</cite><span CLASS="page_no" data-cite="104 uspq 2d 1656" data-cite-type="ReporterOfDecisions" data-cite-pageno="1656" data-primary-citation="104 U.S.P.Q.2d 1641">[**1656]</span>  filed on Jul. 15, 1996, now <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X2I0G071HOJ?jcsearch=U.S.%20Pat.%20No.%205,840,737&amp;summary=yes#jcite">U.S.
    Pat. No. 5,840,737</a>, which claims priority to <cite>U.S. Provisional
    Application Ser. No. 60/009,608</cite> filed on Jan. 4, 1996. This
    application claims priority to all such previous applications, and
    such applications are hereby incorporated herein by reference to the
    extent permitted by law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>988 patent</cite>, coli II.4-15. There is no break in the chain, no flaw in the
entitlement to priority for the common subject matter in the prior copending
filings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Similarly, the '<cite>346 patent</cite> correctly recites the chain of co-pendency.
There are no breaks in the chain:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      This application is a continuation-in-part of U.S. <cite>patent
    application Ser. No. 09/183,422</cite> filed on Oct. 30, 1998, now
    abandoned, which is a continuation-in-part of U.S. <cite>patent
    application Ser. No. 08/680,376</cite> filed on Jul. 15, 1996, now <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Pat.%20No.%205,840,737&amp;summary=yes#jcite">U.S.
    Pat. No. 5,840,737</a>, which claims priority to <cite>U.S. Provisional
    Application Serial No. 60/009,608</cite> filed on Jan. 4, 1996. This
    application claims priority to all such previous applications, and
    such applications are hereby incorporated by reference.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<cite>346 patent</cite>, col.1 ll.4-12.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The novel ground of invalidity here adopted was not accepted by the PTO.
During examination, the patent examiner reviews the priority claims, as
instructed by the Manual of Patent Examining Procedure &sect; 201.08, 201.11. The
examiner did not cite the <cite>'737 patent</cite> against the later applications in the
chain, during either the initial examination of the continuing applications,
or on the reexamination of the <cite>'885 patent</cite> during this litigation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  From the court's incorrect ruling that the <cite>'737 patent</cite> is a reference
against its common subject matter in the later applications in the chain of
filings, I respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  PATENTABILITY &mdash; OBVIOUSNESS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Again ignoring the presumptions and burdens of proof for duly granted
patents, the panel majority holds many of the remaining claims in the
Phillips patents invalid for obviousness over the prior art. Although the
expert witnesses for both sides agreed that it was uniformly understood that
a protective enteric coating is essential for oral dosage, my colleagues
find it obvious to omit the protective enteric coating.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Many scientists studying PPI degradation by stomach acid consistently
confirmed that for practical administration the PPI must be coated with a
gastric acid-resistant coating. Nonetheless, the panel majority <span CLASS="page_no" data-cite="2012 bl 224969 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> cites these
same scientific studies of PPI degradation in the stomach, and concludes
that they render obvious the omission of the enteric coating. My colleagues
do not mention the testimony of experts in PPI science, that the Phillips
uncoated formulation was "weird," "different," "pretty surprising," and "got
people's attention," in the words of Dr. Brian Fennerty. Nor do my
colleagues mention the plethora of patents and publications that uniformly
stated that the PPI must be enteric coated. <i>E.g.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/1?citation=U.S.%20Patent%20No.%204,786,505&amp;summary=yes#jcite">U.S. Patent

No. 4,786,505</a><span CLASS="page_no" data-cite="694 f 3d 1363" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1363" data-primary-citation="694 F.3d 1344">[*1363]</span>  to Lovgren and Pilbrant, col.1 ll.48-51 ("In order to obtain a
pharmaceutical dosage form of omeprazole which prevents omeprazole from
contact with acidic gastric juice, the cores <i>must</i> be enteric coated.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority cites a study of stomach acid degradation of PPI led by
Dr. Pilbrant, and ignores their conclusion that for oral administration the
PPI <i>must</i> be enteric coated. This study by Pilbrant and Cederberg,
"Development of an oral formulation of omeprazole," 20 <i>Scand. J.</i>
<i>Gastroenterology</i> 113 (1985) (herein <i>Pilbrant</i>), explains the scientists'
studies of the rate and conditions of PPI degradation by stomach acid. Drs.
Pilbrant and Cederberg reported that the only way they obtained adequate
absorption of uncoated PPI from the stomach was to require an initial ten
hours of fasting in order to deplete the amount of acid in the stomach, then
to drink a sodium bicarbonate solution to neutralize any remaining acid,
then to drink buffered omeprazole rinsed down with sodium bicarbonate
solution, followed by drinking three more doses of sodium bicarbonate
solution over the next thirty minutes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Pilbrant described various procedures whereby he attempted to avert or
slow PPI degradation by stomach acid, and his conclusion that the rapid acid
degradation "ruled out" an uncoated "conventional oral dosage form." <i>Id.</i> at
114. Dr. Pilbrant concluded that an "enteric-coated dosage form, which does
not release the active ingredient for dissolution and absorption until it
has been transported down to the neutral reacting part of the small
intestine, offers the best possibilities." <i>Id.</i> Dr. Pilbrant recognized that
the complex system whereby uncoated PPI required lengthy fasting and
successive consumption of several liquid doses, was not a practical regimen
for administration to patients, and his "efforts were, therefore,
concentrated on developing an, enteric-coated granule formulation." <i>Id.</i> at
115.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite these teachings, the panel majority holds that this Pilbrant
article renders obvious Dr. Phillips' elimination of the enteric coating. My
colleagues state that Dr. Pilbrant recommended an oral un-coated suspension
as the "second best choice." Maj. op. at 1355. That is a
mis-characterization, for Dr. Pilbrant made no such recommendation; he was
discussing a "reference formulation" for studies of omeprazole in animals
and human subjects:
<span CLASS="page_no" data-cite="104 uspq 2d 1657" data-cite-type="ReporterOfDecisions" data-cite-pageno="1657" data-primary-citation="104 U.S.P.Q.2d 1641">[**1657]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The solubility and stability properties of omeprazole <i>prevent the</i>
    <i>use of water solutions as the reference formulation</i> in animal and
    human studies. A rapidly dissolving suspension <span CLASS="page_no" data-cite="2012 bl 224969 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> of micronized
    omeprazole is the second best choice <i>as the reference formulation.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Pilbrant</i> at 116 (emphases added). Dr. Pilbrant explained why water could not
be used as the reference formulation:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      In animal experiments and in initial studies in man it is highly
    preferable to use water solutions of the drug in order to avoid
    influences of the dosage form on the pharmacokinetics and
    pharmacodynamics of the drug. Omeprazole is, however, only soluble
    in alkaline water solutions with physiologically unacceptable,
    high-pH values.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Pilbrant</i> at 114. The Pilbrant publication stated that a liquid suspension of
micronized omeprazole is second best to a water solution as an experimental
reference formulation, not, as the majority incorrectly contends, that a
nonenteric suspension is a usable "second best" to enteric coated forms for
administration to patients. Maj. op. at 1355-56.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In determining obviousness, "a court must determine whether, at the time
of the invention, a person having ordinary skill in the art would have had
reason to attempt to make the composition" and "a reasonable
<span CLASS="page_no" data-cite="694 f 3d 1364" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1364" data-primary-citation="694 F.3d 1344">[*1364]</span> 
expectation of success in doing so." <i>Procter &amp; Gamble Co. v. Teva Pharms.</i>
<i>USA Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d 989</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">995</a> (Fed.Cir.2009). The presumption of validity
under "<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEJ050003?jcsearch=35%20Usc%20282&amp;summary=yes#jcite">&sect; 282</a> requires an invalidity defense to be proved by clear and
convincing evidence." <i>Microsoft Corp. v. i4i Ltd.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">___ U.S. ___</a>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2242</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011). <i>See </i><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1FI916003?jcsearch=131%20S.%20Ct.%202238&amp;summary=yes#jcite">id. at 2245</a> ("[T]here is a
presumption of validity, a presumption not to be overthrown except by clear
and cogent evidence." (quoting <i>Radio Corp. v. Radio Eng'g Labs., Inc.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5BV14?jcsearch=293%20us%201&amp;summary=yes#jcite">293 U.S. 1</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5BV14?jcsearch=293%20us%201&amp;summary=yes#jcite">3</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5BV14?jcsearch=55%20supreme%20court%20928&amp;summary=yes#jcite">55 S.Ct. 928</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5BV14?jcsearch=79%20l%20ed%20163&amp;summary=yes#jcite">79 L.Ed. 163</a> (1934))); <i>Sciele Pharma Inc. v.</i>
<i>Lupin Ltd.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1HUK5A003?jcsearch=684%20f%203d%201253&amp;summary=yes#jcite">684 F.3d 1253</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1HUK5A003?jcsearch=684%20f%203d%201253&amp;summary=yes#jcite">1260</a> (Fed.Cir.2012) ("The presumption of validity
found in <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282&amp;summary=yes#jcite">&sect; 282</a> is reflected in the standard of proof required to prove
invalidity, clear and convincing evidence.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The prior art and the expert witnesses were explicit and uniform, that
benzimidazole PPIs require an enteric coating for practical oral
administration to patients. Proceeding contrary to the accepted scientific
knowledge is "strong evidence of non-obviousness." <i>W.L. Gore &amp; Associates,</i>
<i>Inc. v. Garlock, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XAC5TJ?jcsearch=721%20f%202d%201540&amp;summary=yes#jcite">721 F.2d 1540</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XAC5TJ?jcsearch=721%20f%202d%201540&amp;summary=yes#jcite">1552</a> (Fed. Cir.1983). There was no
evidence contrary to the position that an enteric coating was believed to be
necessary.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This is a classical example of "teaching away," when persons in the field
of the invention "would be led in a direction divergent from the path that
was taken by the applicant." <i>Ricoh Co., Ltd. v. Quanta Computer Inc.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1AACQ6003?jcsearch=550%20f%203d%201325&amp;summary=yes#jcite">550 F.3d 1325</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1AACQ6003?jcsearch=550%20f%203d%201325&amp;summary=yes#jcite">1332</a> (Fed. Cir.2008). The principal reference relied on by
the panel majority concluded that an "enteric-coated dosage form, which
releases omeprazole for absorption in the small intestine . . . offers the
best possibilities." <i>Pilbrant</i>, at 114-15. This conclusion was repeated in a
patent of which Dr. Pilbrant is an inventor, entitled "Pharmaceutical
Preparation for Oral Use." This patent refers to the studies in the <i>Pilbrant</i>
article, and states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      From what is said about the stability properties of omeprazole [in
    the article], it is obvious that an oral dosage form of omeprazole
    <i>must</i> be protected from contact with the acid reacting gastric juice
    in order to reach the small intestine without degradation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X21P0C5018J?jcsearch=usp%204786505&amp;summary=yes#jcite">U.S. Patent No. 4,786,505</a>, col.1 ll.35-39 (emphasis added). Undaunted by Dr.
Pilbrant'<span CLASS="page_no" data-cite="2012 bl 224969 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> s unequivocal statements, my colleagues creatively find that
<i>Pilbrant</i> teaches that "suspensions of buffered nonenteric coated omeprazole
. . . are a viable alternative to enteric coating." Maj. op. at 1355-56.
Rather, Dr. Pilbrant reinforced the prevailing belief that the omeprazole
<i>must</i> be enteric coated to prevent contact with acidic gastric juice.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The panel majority also cites an article by Lamers <i>et al.</i> entitled
"Absorption of omeprazole in Zollinger-Ellison syndrome is accelerated by
alkali," published in 26 <i>Gut</i> 1134-35 (1985). Lamers studied the absorption
into the blood of coated and uncoated omeprazole in bicarbonate and saline
solutions, based on experiments involving uncoated omeprazole taken with
large volumes of sodium bicarbonate solution (as did Pilbrant). Lamers
stated: "We therefore conclude that addition of alkali accelerates
absorption of omeprazole in patients with Zollinger-Ellison syndrome."
Lamers, like Pilbrant, did not propose that uncoated omeprazole was a viable
alternative for oral administration to patients.
<span CLASS="page_no" data-cite="104 uspq 2d 1658" data-cite-type="ReporterOfDecisions" data-cite-pageno="1658" data-primary-citation="104 U.S.P.Q.2d 1641">[**1658]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For years after the discovery of the benzimidazole PPI products, an
enteric coating was believed to be essential for oral administration to
patients. Pilbrant and Lamers and others did not change that belief; they
reinforced it. The Court has cautioned against "the distortion caused by
hindsight bias" and "arguments reliant upon <i>ex post</i> reasoning" in
determining obviousness. <i>KSR Int'l Co., v. Teleflex</i>,
<span CLASS="page_no" data-cite="694 f 3d 1365" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1365" data-primary-citation="694 F.3d 1344">[*1365]</span> 
<i>Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">421</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The word "must" appears throughout the literature on enteric coating for
benzimidazole PPIs, all ignored by the panel majority. In earlier litigation
concerning omeprazole, this court observed that "an omeprazole formulation
needs a protective enteric coating." <i>In re Omeprazole Patent Litig.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X16NCLC003?jcsearch=483%20f%203d%201364&amp;summary=yes#jcite">483 F.3d 1364</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X16NCLC003?jcsearch=483%20f%203d%201364&amp;summary=yes#jcite">1367</a> (Fed.Cir.2007). Although sodium bicarbonate was known to
stabilize PPI's, it was the accepted understanding that an enteric coating
was needed to avoid rapid degradation by stomach acid. For example, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X308CC3210J?jcsearch=usp%206136344&amp;summary=yes#jcite">U.S.
Patent No. 6,136,344</a> to Depui, issued in 2000, states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      It is well known that proton pump inhibitors are susceptible to
    degradation/transformation in acid reacting and neutral media. In
    respect of the stability properties, it is obvious that one of the
    active substances being a proton pump inhibitor <i>must</i> be protected
    from contact with acidic gastric juice by an enteric coating layer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X308CC3210J?jcsearch=usp%206136344&amp;summary=yes#jcite">344 patent</a>, col.1 ll.62-67.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The teachings are uniform and uncontradicted, that the PPI must be coated.
These teachings surely teach away from elimination of the enteric coating in
oral dosing to patients. The panel majority ignores this general knowledge
and general acceptance, although it is reiterated and uncontradicted
throughout the litigation record.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The references on which the panel majority relies are studies of the rate
and mechanism of gastric acid destruction of the uncoated PPI. Before Dr.
Phillips' invention, no uncoated PPI formulation was achieved for patient
use. The Phillips formulation eluded the experts, despite the extensive
study of PPI degradation, despite the value and <span CLASS="page_no" data-cite="2012 bl 224969 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> importance of PPI
medications. <i>See Unigene Labs., Inc. v. Apotex, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1G4JFM003?jcsearch=655%20f%203d%201352&amp;summary=yes#jcite">655 F.3d 1352</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1G4JFM003?jcsearch=655%20f%203d%201352&amp;summary=yes#jcite">1360-61</a>
(Fed. Cir.2011) ("The statutory criterion is whether the invention would
have been obvious to persons of ordinary skill at the time of the invention,
not whether it is sufficiently simple to appear obvious to judges after the
discovery is finally made.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  My colleagues' hindsight pronouncements of obviousness are based on their
knowledge of Dr. Phillips' achievement, an achievement that was deemed
"weird" and met with incredulity. Determination of obviousness includes
whether the prior art suggested, to a person of ordinary skill in the field
of the invention, that the method "should be carried out and would have a
reasonable likelihood of success." <i>Rockwell Int'l Corp. v. United States</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X37O9L?jcsearch=147%20f%203d%201358&amp;summary=yes#jcite">147 F.3d 1358</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X37O9L?jcsearch=147%20f%203d%201358&amp;summary=yes#jcite">1366</a> (1998) (quoting <i>In re Dow Chem. Co.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3I53R?jcsearch=837%20f%202d%20469&amp;summary=yes#jcite">837 F.2d 469</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X3I53R?jcsearch=837%20f%202d%20469&amp;summary=yes#jcite">473</a>
(Fed.Cir.1988)). The prior art shows the uniform belief that oral
administration of uncoated PPI is not an effective therapeutic alternative.
Dr. George Sachs<a HREF="#fn101" name="fnref_fn101">[fn1]</a> publicly criticized the Santarus approach:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The principle of Santarus is to give essentially, if you like, a
    bicarbonate or carbonate buffer to the omeprazole solution. And so
    you don't have enteric coating and it comes in a gelcoat or gelcap.
    We thought about that a long time ago at Astra. . . . Man is a
    continuous acid secretor; the amount of acid man makes is not really
    predictable and so you're not really able to particularly buffer the
    omeprazole solution in the stomach. So as soon as the solution
<span CLASS="page_no" data-cite="694 f 3d 1366" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1366" data-primary-citation="694 F.3d 1344">[*1366]</span> 
    starts to fall below pH 5, which would happen with a high degree of
    frequency, you simply destroy the omeprazole and it will no longer
    work. So I think the Santarus principle, though well-found-ed &mdash; you
    know, in terms of the idea of stabilizing, simply doesn't work in
    man.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Trial Tr. 23:1-20; J.A. 3672; <i>Santarus</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1D1UBK003?jcsearch=720%20f%20supp%202d%20427&amp;summary=yes#jcite">720 F.Supp.2d at 456</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Phillips "proceeded contrary to the accepted wisdom. . . . That fact
is strong evidence of nonobviousness." <i>W.L. Gore</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XAC5TJ?jcsearch=721%20f%202d%201540&amp;summary=yes#jcite">721 F.2d at 1552</a> (citing
<i>United States v. Adams</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6FA?jcsearch=383%20us%2039&amp;summary=yes#jcite">383 U.S. 39</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6FA?jcsearch=86%20supreme%20court%20708&amp;summary=yes#jcite">86 S.Ct. 708</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X5C6FA?jcsearch=15%20l%20ed%202d%20572&amp;summary=yes#jcite">15 L.Ed.2d 572</a> (1966)).
<i>See also Standard Oil Co. v. American Cyanamid Co.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X4A9P3?jcsearch=774%20f%202d%20448&amp;summary=yes#jcite">774 F.2d 448</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X4A9P3?jcsearch=774%20f%202d%20448&amp;summary=yes#jcite">454</a>
(Fed.Cir.1985) ("A <span CLASS="page_no" data-cite="104 uspq 2d 1659" data-cite-type="ReporterOfDecisions" data-cite-pageno="1659" data-primary-citation="104 U.S.P.Q.2d 1641">[**1659]</span> person of ordinary skill in the art is also presumed to
be one who thinks along the line of conventional wisdom in the art."); <i>Artie</i>
<i>Lures, Inc. v. Gene Larew Tackle, Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XACAAI?jcsearch=119%20f%203d%20953&amp;summary=yes#jcite">119 F.3d 953</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XACAAI?jcsearch=119%20f%203d%20953&amp;summary=yes#jcite">958</a> (Fed.Cir.1997)
("conventional wisdom that a combination should not be made is evidence of
unobviousness").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Skepticism within the industry supports unobviousness of the invention.
<i>See Transocean Offshore Deepwater Drilling, Inc. v. Maersk Contractors USA,</i>
<i>Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">617 F.3d 1296</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1E2RA2003?jcsearch=617%20f%203d%201296&amp;summary=yes#jcite">1304</a> (Fed.Cir.2010) (objective evidence of
nonobviousness included "evidence of industry skepticism."). This
skepticism, reinforced in scientific commentary and conceded by the experts,
leaves no doubt that an enteric coating was believed necessary for oral PPI
administration. <i>See DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.</i>,
<a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1B5GUU003?jcsearch=567%20f%203d%201314&amp;summary=yes#jcite">567 F.3d 1314</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1B5GUU003?jcsearch=567%20f%203d%201314&amp;summary=yes#jcite">1326</a> (Fed.Cir.2009) (for an obvious combination, skilled
artisans must have expected that the combination would work for its intended
purpose).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The record states that the Phillips formulation provides effective
absorption of the PPI directly from the stomach into the bloodstream, that
it achieves faster control of stomach acid, improved nocturnal acid control,
dosing independent <span CLASS="page_no" data-cite="2012 bl 224969 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> of meals, and stabilized pharmacodynamics. The direct
absorption from the stomach has the advantages of rapid and consistent
bioavailability and increased effectiveness, as well as ease of
administration to patients unwilling or unable to swallow capsules or
tablets, as the Phillips patents explain:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [I]n their current form (capsules containing enteric-coated
    granules or enteric-coated tablets), proton pump inhibitors can be
    difficult or impossible to administer' to patients who are either
    unwilling or unable to swallow tablets or capsules, such as
    critically ill patients, children, the elderly, and patients
    suffering from dysphagia.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<cite>772 Patent</cite>, col.7 l.65-col.8 l.4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  These advantages are reflected in the Santarus sales growth of Zegerid&reg;
from $46 million in 2006 to over $100 million in 2008. The record states
that numerous companies took a license to the Phillips patents. Elvidence of
"how the patented device is viewed by the interested public: not the
inventor, but persons concerned with the product in the objective arena of
the marketplace" is "highly probative of the issue of nonobviousness." <i>Arkie</i>
<i>Lures</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XACAAI?jcsearch=119%20f%203d%20953&amp;summary=yes#jcite">119 F.3d at 957</a>. In <i>Ashland Oil, Inc. v. Delta Resins &amp; Refractories,</i>
<i>Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XABR7B?jcsearch=776%20f%202d%20281&amp;summary=yes#jcite">776 F.2d 281</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/XABR7B?jcsearch=776%20f%202d%20281&amp;summary=yes#jcite">306</a> (Fed.Cir.1985), this court observed that: "Secondary
considerations may be the most pertinent, probative, and revealing evidence
available to the decision maker in reaching a conclusion on the
obviousness/nonobviousness issue."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The uniform belief was that an enteric coating is necessary for oral
administration of PPIs to patients. Despite this universal skepticism, my
colleagues on this panel find Dr. Phillips' invention obvious to them. I
respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> The record states that Dr. Sachs was awarded the Beaumont Prize, one
of the highest honors of the American Gastrological Association, and was
described at the trial as "the dean of PPIs." <i>See Altana Pharma AG v. Teva</i>
<i>Pharms. USA Inc.</i>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">566 F.3d 999</a>, <a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">1009</a> (Fed. Cir.2009) (stating that Dr. Sachs
"is one of the leading researchers in the PPI development field").
</p></div>
<!--BBLS DD 1724924166147-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I6ENS003/history">Direct History (2)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I6ENS003/analysis">Case Analysis (9)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I6ENS003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
7
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I6ENS003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
2
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Reversed (In Part), Case Remanded, Judgment Affirmed (In Part) (Per Curiam)</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceuticals</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1Q6LC8P4M82">10-01360 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/7c87ed6b284de02381b4d0c95e838674/document/X1Q6LC8P4O82">10-01380 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/7c87ed6b284de02381b4d0c95e838674/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "7c87ed6b284de02381b4d0c95e838674";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY76b157&previousPageId=&previousActivityInstanceId=ENTITY3a2dab&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:23:02-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I6ENS003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY3a2dab&previousPageId=&previousActivityInstanceId=ENTITY0d4001&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:22:59-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I6ENS003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I6ENS003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","1850676","3027446"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
